Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | AHCY | P23526 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276285 | 1.00 | ADORA2A (0.47) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL8465291 | 0.71 | ADORA2A (0.47) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL8465200 | 0.71 | ADORA2A (0.47) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL6024012 | 0.71 | LMNA (0.49) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL1393316 | 0.64 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL904363 | 0.64 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL5810639 | 0.64 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL29496348 | 0.64 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL20986028 | 0.62 | ADORA2A (0.51) | ADORA2AADORA1LMNASMN1; SMN2KDM4E | |
| SCHEMBL20986040 | 0.62 | ADORA2A (0.44) | ADORA2AADORA1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785654-B2 | Method for production of N-(2-amino-1,2-dicyanovinyl)imidates, method for production of N-(2-amino-1,2-dicyanovinyl)formamidine, and method for production of aminoimidazole derivatives | NIPPON SODA CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8273899-B2 | Method for production of N-(2-amino-1,2-dicyanovinyl)imidates, method for production of N-(2-amino-1,2-dicyanovinyl)formamidine, and method for production of aminoimidazole derivatives | NIPPON SODA CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8258333-B2 | Method for production of N-(2-amino-1,2-dicyanovinyl)imidates, method for production of N-(2-amino-1,2-dicyanovinyl)formamidine, and method for production of aminoimidazole derivatives | NIPPON SODA CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120142957-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120130083-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20100087655-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NIPPON SODA CO., LTD (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087655-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NAAA, ITPA, GART | ADORA2A 609/4885ADORA1 604/4885LMNA 1944/4885 |
| US-20120142957-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NIT2, NPM1, NAT1 | ADORA2A 2521/4885ADORA1 1346/4885LMNA 2328/4885 |
| US-20120130083-A1 | METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)IMIDATES, METHOD FOR PRODUCTION OF N-(2-AMINO-1,2-DICYANOVINYL)FORMAMIDINE, AND METHOD FOR PRODUCTION OF AMINOIMIDAZOLE DERIVATIVES | NCL, NCLN, NIT2 | ADORA2A 2214/4885ADORA1 1667/4885LMNA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.